These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16849565)

  • 1. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
    Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
    Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
    Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
    Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
    Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
    Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
    Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
    Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication of the A7(74) strain of Semliki Forest virus is restricted in neurons.
    Fazakerley JK; Pathak S; Scallan M; Amor S; Dyson H
    Virology; 1993 Aug; 195(2):627-37. PubMed ID: 8393239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
    Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
    Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
    Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
    Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.
    Määttä AM; Mäkinen K; Ketola A; Liimatainen T; Yongabi FN; Vähä-Koskela M; Pirinen R; Rautsi O; Pellinen R; Hinkkanen A; Wahlfors J
    Int J Cancer; 2008 Oct; 123(7):1704-11. PubMed ID: 18651570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent oncolytic activity of human enteroviruses against human prostate cancer.
    Berry LJ; Au GG; Barry RD; Shafren DR
    Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.
    Duerner LJ; Schwantes A; Schneider IC; Cichutek K; Buchholz CJ
    Gene Ther; 2008 Nov; 15(22):1500-10. PubMed ID: 18509380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
    Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
    J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
    Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
    Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.